Skip to main
EVAX
EVAX logo

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS demonstrates a strong financial outlook based on the promising efficacy and safety profile of its lead product, EVX-01, which has shown a 75% objective response rate (ORR) in combination with pembrolizumab, an improvement from 69% reported previously. The accuracy of the company’s AI predictive models, particularly the PIONEER model, has also improved, with 81% of predicted neoantigens proving to be immunogenic, reinforcing Evaxion's leadership in the neoantigen cancer vaccine sector. Moreover, a significant percentage of patients (54%) experienced deepening responses following treatment, showcasing the potential for long-term effectiveness and the transformative impact of Evaxion's proprietary technologies on patient outcomes.

Bears say

Evaxion AS experienced a negative market reaction to their strong data update for the EVX-01 despite the promising developments in their clinical-stage oncology pipeline. The disappointment appears to stem from investors seeking a more definitive indication of EVX-01's contribution to the company's future performance. This uncertainty around product impact highlights a potential risk in the stock's performance relative to the company's projected advancements in immunotherapy.

EVAX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 3 analysts, EVAX has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.